The liver is highly susceptible to a number of pathological insults, including ischemia/reperfusion injury. One of the striking consequences of liver injury is the associated pulmonary dysfunction that may be related to the release of hepatic-derived cytokines. We have previously employed an animal model of hepatic ischemia/reperfusion injury, and demonstrated that this injury causes the production and release of hepaticderived TNF, which mediates a neutrophil-dependent pulmonary microvascular injury. In this study, we have extended these previous observations to assess whether an interrelationship between TNF and the neutrophil chemoattractant/activating factor, epithelial neutrophil activating protein-78 (ENA-78), exists that may be accountable for the pathology of lung injury found in this model. In the context of hepatic ischemia/reperfusion injury, we demonstrated the following alterations in lung pathophysiology: (a) an increase in pulmonary microvascular permeability, lung neutrophil sequestration, and production of pulmonary-derived ENA-78; (b) passive immunization with neutralizing TNF antiserum resulted in a significant suppression of pulmonary-derived ENA-78; and (c) passive immunization with neutralizing ENA-78 antiserum resulted in a significant attenuation of pulmonary neutrophil sequestration and microvascular permeability similar to our previous studies with anti-TNF. These findings support the notion that pulmonary ENA-78 produced in response to hepatic-derived TNF is an important mediator of lung injury.
Introduction
Ischemia/reperfusion injury is involved in the pathophysiology of many clinical disorders including myocardial infarction, stroke, mesenteric ischemia, peripheral vascular disease, organ transplantation, and circulatory shock. This latter condition followed by resuscitation precipitates a systemic response resembling ischemia/reperfusion injury, and often leads to the adult respiratory distress syndrome and multiple organ system failure syndrome ( 1) . Clinically, the liver is highly susceptible to hypovolemic shock, and since it has the largest fixed macrophage population in the body, the association of pulmonary dysfunction with liver injury may be related to the release of hepaticderived inflammatory cytokines.
Our laboratory has previously employed an animal model of hepatic ischemia/reperfusion injury, and has demonstrated that hepatic ischemia/reperfusion injury causes the production and release of tumor necrosis factor-alpha (TNF), which in turn mediates a neutrophil-dependent microvascular lung injury (2, 3) . While TNF was initially reported to be a neutrophil chemotaxin (4) , recent studies have shown that recombinant TNF is not directly chemotactic for neutrophils (5, 6) . These earlier findings suggest that cytokine networks may be operative in hepatic ischemia/reperfusion-induced lung injury, such that the initial expression of liver-derived early response cytokines, i.e., TNF, is followed by the generation of more distal neutrophil chemotactic/activating factors.
Recently a group of small proteins with specific neutrophil chemotactic properties, the C-X-C chemokines, have been isolated, cloned, and expressed. These chemokines share significant homology with the conservation of four cysteine amino acid residues, the first pair of cysteines separated by one amino acid residue (C-X-C) (7) . This family includes neutrophil activating peptide-2 (NAP-2),' growth related oncogene (GRO) alpha, GRO-beta, GRO-gamma, interleukin 8 , and epithelial neutrophil activating protein (ENA-78) (8) (9) (10) (11) . This latter chemokine, ENA-78, has been found to be produced by variety of immune and nonimmune cells in response to TNF or interleukin 1 (IL-1) (12) . Thus, both immune and nonimmune cells of the lung may be involved in cytokine cascades with the end result being the expression of appropriate chemokines that enhance neutrophil-dependent inflammatory responses.
We postulated that ENA-78 may account for neutrophil recruitment and extravasation into the lung following hepatic ischemia/reperfusion, resulting in acute pulmonary microvascular injury. In this study, we demonstrate the following: (a) hepatic ischemia/reperfusion injury leads to increased pulmonary mi-crovascular permeability, neutrophil sequestration, and production of ENA-78; (b) neutralization of TNF by passive immunization in the context of hepatic ischemia/reperfusion injury results in the attenuation of the production of pulmonary-derived ENA-78; and (c) neutralization of ENA-78 by passive immunization in the context of hepatic ischemia/reperfusion injury results in significant reduction of pulmonary microvascular permeability and neutrophil sequestration. These findings support the notion that ENA-78 produced in response to hepaticderived TNF is an important mediator of pulmonary microvascular injury and neutrophil sequestration.
Methods
Hepatic ischemia/reperfusion injury model Adult male specific pathogen-free Sprague-Dawley rats (Charles River Laboratories, Portage, MI) weighing 250-300 g were used in all experiments. A rat model of lobar, rather than total, hepatic ischemia/reperfusion was used as previously described (2, 3, 13) . This model induces a severe ischemic insult to the liver without inducing mesenteric venous hypertension and subsequent bacterial translocation into the portal venous blood (2, 14) . Briefly, anesthesia was induced with intramuscular ketamine hydrochloride (100 mg/kg) and maintained with inhalation of methoxyflurane. After intravenous heparinization (200 United States Pharmacopeia U/kg), midline laparotomy was performed and an atraumatic microaneurysm (Heifitz; W. Lorenz, Jacksonville, FL) clip was used to interrupt the portal venous and hepatic arterial blood supply to the cephalad three lobes of the liver. The three caudal lobes retain an intact portal and arterial inflow and venous outflow, preventing intestinal venous congestion. Hepatic ischemia was maintained for 90 min; the Heifitz clip was then removed at a second laparotomy, initiating reperfusion. Previous experiments in our laboratory have demonstrated that 90 min of lobar hepatic ischemia followed by reperfusion induces a severe, isolated, and reproducible liver and associated lung injury without excessive animal mortality at 12 h of reperfusion (2, 3) . However, mortality was 33% at 24 h (2, 3) . Intravenous lactated Ringer's solution (40 ml/ kg) was administered at the conclusion of the second laparotomy to replace operative fluid and blood losses. Sham-operated control animals were treated in an identical fashion with the omission of vascular occlusion. We have previously demonstrated that animals remain normotensive throughout this procedure and that there is no portal venous endotoxemia (2) . Animals were killed at specified times and plasma and tissue processed as described below.
Peripheral blood and tissue procurement
At the time of killing, anticoagulated blood (heparin 50 United States Pharmacopeia U/ml) was obtained via the animal's right ventricle. Plasma was removed after the blood was centrifuged at 2,000 g for 10 min and stored at -70°C for later ENA-78 analysis. The lungs were perfused free of blood with 20 ml of sterile 0.9% normal saline infused via the spontaneously beating right ventricle. The lungs were then removed from the thoracic cavity and separated from the surrounding mediastinal structures. The right lung was homogenized in 5 ml of PBS, pH 7.5, on ice, using a tissue homogenizer (Polytron; Brinkmann Instruments, Westbury, NY). The lung homogenate was centrifugated at 2,000 g for 15 min at 4°C. The aqueous extract was then filtered through a 1.2-Ism filter (Gelman Inc., Ann Arbor, MI) and stored at -70°C for later ENA-78 analysis.
ENA-78 ELISA
Immunoreactive ENA-78 was quantitated using a modification of the double ligand method as previously described (12, 15 Laboratories, Burlingame, CA), incubated for 30 min at 370C, and rinsed with PBS. At this point, sections were then treated with conjugated streptavidin-horseradish peroxidase (Vector Laboratories) and incubated for 30 min at room temperature. The slides were then overlaid with substrate chromogen (3,3'-diaminobenzidine; Vector Laboratories), incubated for 10 min at room temperature to allow for color development, and rinsed with distilled water to stop the reaction. Mayer's hematoxylin was used as a counterstain.
Isolation and RT-PCR amplification of whole-lung mRNA
The right lower lobe of lungs from animals subjected to hepatic ischemia and 2 h of reperfusion or sham laparotomy were snap frozen in liquid nitrogen and stored at -70°C until further analyzed by RT-PCR as previously described (17) . Briefly, total cellular RNA from the lungs was isolated by homogenizing the lungs with a tissue homogenizer in a solution containing 25 mM Tris, pH 8.0, 4.2 M guanidine isothiocyanate, 0.5% sarkosyl, and 0.1 M 2-mercaptoethanol. After homogenization, the suspension was added to a solution containing an equal volume of 100 mM Tris, pH 8.0, 10 mM EDTA, and 1.0% SDS. The mixture was then extracted two times each with phenol-chloroform and chloroformisoamyl alcohol. The RNA was alcohol precipitated and the pellet dissolved in diethyl pyrocarbonate water (Sigma Immunochemicals, St. Louis, MO). Total RNA was determined by spectrophotometric analysis at 260 nm wavelength. 5 qg of total RNA was reverse transcribed into cDNA using an RT kit (GIBCO BRL, Gaithersburg, MD) and oligo (dT) 12-18 primers. The cDNA was then amplified using specific primers for cyclophilin as a control and ENA-78. The primers used were ENA-78 sense: 5 '-AAT-CTG-CAA-GTG-TTC-GCC-ATA-GGC-CCA-CAG-TGC-3'; ENA-78 anti-sense: 5 '-GCA-CTG-TGG-GCC-TAT-GGC-GAA-CAC-TTG-CAG-ATT-3'; cyclophilin sense: 5 '-CAT-CTG-CAC-TGC-CAA-GAC-TG-3'; cyclophilin anti-sense: S'-CTG-CAA-TCC-AGC-TAG-GCA-TG-3'. The amplification buffer contained 50 mM KCl, 10 mM Tris-HCl (pH 8.3), and 2.4 mM MgCl. The specific oligonucleotide primer was added (200 ng/sample) to the buffer, along with 1 p1 of the reverse transcribed cDNA samples. The cDNA was amplified after determining the optimal number of cycles. The mixture was first incubated for 5 min at 940C, and then cycled 27 times at 950C for 30 s, 580( for 45 s, and elongated at 720( for 75 s. This format allowed optimal amplification with little or no nonspecific amplification of contaminating DNA. After amplification, the sample (20 jsl) was separated on a 2% agarose gel containing 0.3 jig/ml (0.003%) of ethidium bromide, and bands were visualized and photographed using ultraviolet transillumination.
Lung permeability analysis
Pulmonary microvascular permeability was measured using a modification of the Evans blue dye extravasation technique as previously described (18) (19) (20) 
Pulmonary neutrophil sequestration
Pulmonary neutrophil infiltration was quantitated using both a myeloperoxidase (MPO) assay and pulmonary tissue morphometric analysis.
Myeloperoxidase assay. The MPO assay was performed as previously described (21) . Briefly, at the time the animals were killed the lungs were perfused free of blood with 20 ml of 0.9% normal saline via the spontaneously beating right ventricle. The left lung was excised and placed in a 50-mM potassium phosphate buffer solution (pH 6.0) with 5% hexadecyltrimethyl ammonium bromide (Sigma Immunochemicals). The pulmonary tissue was homogenized, sonicated, and centrifuged at 12,000 g for 15 min at 4°C. The supernatant was then assayed for MPO activity using a spectrophotometric reaction with O-dianisidine hydrochloride (Sigma Immunochemicals) at 460 nm.
Pulmonary tissue neutrophil morphometrics. Morphometric analysis was performed using a modification of a previously described technique (22 Passive immunization and neutralization of TNF or ENA-78
The effects of neutralization of TNF or ENA-78 in our model were assessed by the administration of a polyclonal rabbit anti-murine TNF or a polyclonal rabbit anti-human ENA-78. The TNF antiserum neutralizes both natural and recombinant TNF, cross-reacts with rat TNF, and has no cross-reactivity with interleukin 1 (23) . The ENA-78 antiserum neutralizes both natural and recombinant ENA-78, cross-reacts with rat ENA-78, and has no cross-reactivity with other members of the C-X-C or C-C chemokine family (12) 
Results
Time course and immunolocalization of pulmonary ENA-78 after hepatic ischemia/reperfusion injury. Using a rat model of lobar hepatic ischemia/reperfusion, we have previously identified a specific neutrophil-mediated pulmonary injury that is associated with the release of hepatic-derived TNF (2, 3, 13 12 an animal subjected to sham laparotomy. ENA-78 mRNA was significantly expressed in the animal subjected to hepatic ischemia followed by 2 h of reperfusion. These data support that 10- ENA-78 is generated in the lung.
Lung injury and pulmonary neutrophil infiltration after he- (Fig. 4 A) . In addition, MPO activity from these lungs was 4-markedly elevated (328±55 mOD/min per g tissue) as compared to sham laparotomy animals (120±45 mOD/min per tissue) (Fig. 4 B) with control serum (P < 0.001). We postulated that TNF may nterestingly, ENA-78 protein appeared to be diffusely loact as an early response cytokine, leading to the production of -d to the entire alveolar-capillary membrane (ACM) in the pulmonary-derived ENA-78. To test this hypothesis, we pasof animals that had undergone hepatic ischemia/reperfusively immunized rats with either control rabbit serum or neuinjury (Fig. 2 C) (Fig. 5) . These results suggested that TNF had y attenuated the immunolocalization of the anti-ENA-78 a significant impact in the lung with respect to the induction of )dies to the lungs of animals that had undergone hepatic pulmonary-derived ENA-78, as neutralization of TNF resulted mia/reperfusion injury (data not shown).
in a twofold reduction in pulmonary ENA-78. D further establish that ENA-78 was lung derived, lungs Neutralization ofENA-78 attenuates lung injury and pulmoanimals subjected to hepatic ischemia followed by 2 h of nary neutrophil sequestration. We next postulated that ENAusion or sham laparotomy were snap frozen and total 78 may act as a more distal proinflammatory cytokine for the isolated and subjected to RT-PCR for the detection of induction of this neutrophil-mediated pulmonary injury. To test 78 mRNA (Fig. 3) . Lanes 1 and 4 are control (cyclophilin this hypothesis, animals were given either control rabbit serum k) and ENA-78 mRNA, respectively, from the lung of or neutralizing anti-ENA-78 serum immediately before hepatic imal subjected to hepatic ischemia followed by 2 h of ischemia. The pulmonary effects of neutralizing ENA-78 are usion, while lanes 2 and 5 are control (cyclophilin presented in Fig. 6. Fig. 6 ,A, B, and C are the histopathological k) and ENA-78 mRNA, respectively, from the lung of changes in the lungs of sham-operated controls, hepatic isch- emia/reperfusion animals who had received control serum, and hepatic ischemia/reperfusion animals who were passively immunized with neutralizing antibodies to ENA-78, respectively. Lung permeability, MPO activity, and neutrophil morphometric analysis were also assessed after 12 h of hepatic reperfusion. As 1 2 3 4 5 shown in Fig. 7 A, neutralizing anti-ENA-78 serum significantly attenuated (2.7-fold) the lung permeability index from 2.54+0.45 to 0.94±0.07, equivalent to sham-operated animal lungs. In a comparable manner, MPO activity (344.5±20 mOD/ min per g tissue to 260±9.7 mOD/min per g tissue) and neutrophil morphometrical analysis (3.3 ±0.25 PMN/HPF to 1.7±0.16 PMN/HPF) demonstrated similar changes in response to neutralizing anti-ENA-78 serum (Fig. 7 B and C,  respectively) . Interestingly, neutralizing anti-ENA-78 serum failed to attenuate MPO activity measured in the lungs at 1 h after hepatic reperfusion (data not shown). These findings support the notion that pulmonary-derived ENA-78 produced in the context of hepatic ischemia/reperfusion injury is a major mediator of subsequent lung injury.
Discussion
One of the salient features of acute pulmonary microvascular injury precipitated by hepatic ischemia/reperfusion appears to be related to pulmonary neutrophil sequestration (2, 3) . Activated ing hepatic ischemia/reperfusion (n = 7) had a significantly increased PI as compared to sham operated control animals (n = 7, * P < 0.005). B demonstrates pulmonary myeloperoxidase (MPO) levels in animals sub-B jected to hepatic ischemia/reperfusion as compared to sham-operated control animals (n = 5 in both groups, * P < 0.05). C demonstrates pulmonary tissue morphometrics for the presence of neutrophils from animals subjected to he-C patic ischemia/reperfusion versus sham laparotomy (*P < 0.001).
tiple organ system failure syndrome, regardless of the precipitating event (5, (24) (25) (26) . Activated neutrophils release a variety of inflammatory mediators, including proteolytic enzymes, arachidonic acid metabolites, reactive oxygen species, and cytokines; these mediators can impact directly on the pulmonary microvasculature, leading to increased pulmonary microvascu- Figure 5 . The effect of neutralization of TNF on pulmonary ENA-78 levels after 6 h of hepatic reperfusion. Pulmonary ENA-78 levels were significantly attenuated in animals passively immunized with rabbit anti-TNF serum before the initiation of hepatic ischemia/reperfusion (n = 3) as compared to animals receiving control serum (n = 3, * P < 0.005). "Sham" (n = 3) is the sham-operated animals that did not receive either the control or neutralizing rabbit anti-TNF sera. Figure 6 Photomicrograph of the effects of neutralization of ENA-78 on hepatic ischemia/reperfusion-induced lung injury. A, B, and C show the histopathologic changes in the lungs of sham-operated controls, hepatic ischemia/reperfusion animals who had received control serum, and hepatic ischemia/reperfusion animals who were passively immunized with neutralizing antibodies to ENA-78, respectively (1 im sections stained with toluidine blue, X400). lar permeability, pulmonary hemorrhage, and increased leukocyte migration into the pulmonary interstitium (5, 24, (26) (27) (28) . Our laboratory has previously used a rat model of lobar hepatic ischemia/reperfusion and has identified pathophysiologic events in the lung that were associated with the release of hepatic-derived TNF (2, 3) . These findings were unassociated with translocation of bacterial or circulating portal venous endotoxin (2) . While these investigations were important in estab- (5, 6) . This observation would suggest that potential cytokine networks are operative in vivo and are dependent upon the initial generation of TNF, followed by the production of additional cytokines that may influence neutrophil chemotaxis/activation. This hypothesis has been substantiated with the discovery of a superfamily of small proteins with specific neutrophil chemotactic properties (7) . These chemotactic cytokines, or chemokines, share significant homology with a family of polypeptides that possess four conserved cysteine amino acid residues, the first pair of cysteines separated by one amino acid residue (C-X-C) (7). In general, this family has potent neutrophil chemotactic/activating properties, such as the induction of the respiratory burst, exocytosis, generation of arachidonic acid metabolites, shedding of L-selectin, and expression of f2-integrins (CDl lb/ CD18 complex) (7) . The chemokines with specific neutrophil activating properties include NAP-2, GRO-alpha, GRO-beta, GRO-gamma, IL-8, and ENA-78 (8) (9) (10) (11) . This latter chemokine in vitro has been found to be produced by a number of immune and nonimmune cells, including endothelial cells, neutrophils, monocytes, pulmonary epithelial cells, and pulmonary fibroblasts in response to TNF or IL-1 (8, 12) . These previous findings support the concept that both immune and nonimmune cells of the lung have the capacity to produce chemokines that contribute to the pathogenesis of pulmonary injury via the elicitation and activation of neutrophils.
In our current investigation, we have extended our previous studies of hepatic ischemia/reperfusion-induced lung injury and determined whether an interrelationship of TNF and ENA-78 exists that could account for the development of lung injury. We found a time-dependent production of pulmonary-derived ENA-78, in the context of hepatic ischemia/reperfusion injury, that was significantly expressed during significant pulmonary microvascular permeability and neutrophil sequestration. Immunolocalization of ENA-78 within the lung was associated with a staining pattern that included cells of the entire ACM. This finding was intriguing and suggested that all of the cellular constituents of the ACM could express ENA-78. However, this pattern of immunolocalization could also have been explained by the presence of ENA-78 bound to the extracellular matrix of the ACM. ENA-78, similar to other members of the C-X-C chemokine family can bind to heparin and, in vivo, may have been bound to the glycosoaminoglycans within the extracellular matrix (7, 8, 12) . In addition, immunolocalization within the lung was specific for ENA-78 since our antibodies do not crossreact with other C-X-C or C-C chemokine family members and preabsorption of these antibodies to human ENA-78 before the performance of immunohistochemical staining completely abrogated their ability to immunolocalize ENA-78 in rat lung.
Previously, we found that neutralization of TNF resulted in significant attenuation of lung injury in association with hepatic ischemia/reperfusion injury (2, 3) . In this study, we found that neutralizing TNF was efficacious in inhibiting pulmonary expression. This finding supported the notion that a TNFdependent induction of pulmonary ENA-78 may be a mechanism that contributes to the pathogenesis of pulmonary injury. To test this premise, in vivo neutralization of ENA-78 by passive immunization resulted in significant attenuation of both pulmonary microvascular permeability and neutrophil infiltration in the lung. These findings were comparable to our previous studies (2, 3) , suggesting that ENA-78, and perhaps other members of the C-X-C chemokine family, may represent more distal mediator(s) in a series of events initiated by TNF.
One can speculate, in the context of hepatic ischemia/reperfusion injury, that the mechanisms involved in neutrophil elicitation, activation, and ensuing neutrophil-mediated microvascular injury in the lung, are dependent upon a cascade of events.
Hepatic ischemia/reperfusion injury leads to early TNF production and the release of this potent mediator into the pulmonary microvasculature, causing pulmonary endothelial activation with the expression of adhesion molecules. Subsequently, TNF can simultaneously induce the local generation of ENA-78 or potentially other members of the C-X-C chemokine family, resulting in neutrophil activation and upregulation of the neutrophil-derived 32-integrin (CDllb/CD18). The interaction of CDllb/CD18 complex with its receptor/ligand, intracellular adhesion molecule-i, on the pulmonary endothelium results in firm adhesion of neutrophils to the endothelium (7, 29, 30) . The subsequent steps leading to neutrophil transendothelial migration and extravasation into the interstitium of the lung may be dependent upon both the continued expression of /2-integrins and neutrophil migration along an established ENA-78 concentration gradient. Finally, activation and influx of neutrophils into the pulmonary interstitium by ENA-78 or potentially other members of the C-X-C chemokine family can result in a neutrophil-mediated pulmonary microvascular injury. Thus, our findings demonstrate the importance of a C-X-C chemokine (ENA-78) in mediating a TNF-dependent pulmonary injury in the context of hepatic ischemia/reperfusion-induced pulmonary injury in the rat.
